Spruce Biosciences, Inc. $SPRB

What the company doesAI summary of filing

Spruce Biosciences is a biopharmaceutical company developing therapies for neurological disorders with significant unmet medical need. The company's lead product candidate is tralesinidase alfa enzyme replacement therapy (TA-ERT) for Mucopolysaccharidosis Type IIIB (MPS IIIB), a rare genetic disease; the company has completed Phase 1/2 and extension studies and plans to submit a biologics license application (BLA) to the FDA in the fourth quarter of 2026, with a confirmatory Phase 3 trial to be initiated during BLA review. The company is also developing tildacerfont and a companion diagnostic called Cortibon for major depressive disorder, and SPR202 for congenital adrenal hyperplasia. The company is currently pre-revenue and has indicated substantial doubt about its ability to continue as a going concern due to insufficient working capital. [10-K 2026-03-09]

Segments: TA-ERT for Mucopolysaccharidosis Type IIIB (MPS IIIB), Tildacerfont and Cortibon for Major Depressive Disorder, SPR202 for Congenital Adrenal Hyperplasia